Related Experiment Videos
CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis
British Journal of Rheumatology
|July 3, 1998
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.
Rheumatology (Oxford, England)·2024
Nutrition therapy in intensive care unit setting: what can be learned from a 6 months survey in a large academic hospital?
Annali di igiene : medicina preventiva e di comunita·2020
Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database.
Scandinavian journal of rheumatology·2018
Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection.
British journal of rheumatology·1999
Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients.
British journal of rheumatology·1999
Circulating interleukin-16 in systemic lupus erythematosus.
British journal of rheumatology·1999
Antibodies to Klebsiella pneumoniae lipopolysaccharide in patients with ankylosing spondylitis.
British journal of rheumatology·1999
Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years.
British journal of rheumatology·1999
A study of the frequency of pericardial and pleural effusions in scleroderma.
British journal of rheumatology·1999
Development of cecal volvulus after redo pancreas transplantation.
Journal of surgical case reports·2026
Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.
Iranian journal of otorhinolaryngology·2026
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.
Research and practice in thrombosis and haemostasis·2026